MSH|^~\&|LAB|RCH|||202003181346||ORU^R01|4187692|D|2.3|||AL|NE
PID|1||RC00008163|RC7824|FHLOOSEN^PLIS^||19240204|M||||||||||RC001189/19|9698717831
OBR|1|40654^LAB|00030643^1803:H00003R^LAB^180320:H3^40654|210.2700^ANA^Anti-Nuclear Antibody Group^^^5047-6||202003181346|202003181342|||||||202003181342||||||||||LAB|F||||
OBX|1|ST|210.2850^ANAS R^ANA Screen^^5047-6^5047-6|1|0.5^^Y||<0.7|N||A^S|F|||202003181346
NTE|1||Antinuclear antibodies, including antibodies to dsDNA or to
NTE|2||extractable nuclear antigens (SS-A, SS-B, Sm, U1RNP, Scl-70,
NTE|3||Jo-1, and Centromere), are not present.
NTE|4||
NTE|5||Further testing is not indicated; however, if required,
NTE|6||please contact a Hematopathologist.
OBR|2|40654^LAB|00030643^1803:H00003R^LAB^180320:H3^40654|210.3200^DNA^Anti-dsDNA Antibody Group^^^32677-7||202003181346|202003181342|||||||202003181342||||||||||LAB|F||||
OBX|1|ST|210.3290^DNAS R^Anti-DNA (Double Stranded)^^32677-7^32677-7|1|9.0^^Y|IU/mL|<10.0|N||A^S|F|||202003181346
OBR|3|40654^LAB|00030643^1803:H00003R^LAB^180320:H3^40654|210.7000^APCA^Anti-Parietal Cell Antibody^^^26969-6||202003181346|202003181342|||||||202003181342||||||||||LAB|F||||
OBX|1|ST|210.7100^APCAS^Anti-Parietal Cell Antibody^APCA^26969-6^26969-6|1|Positive^^N||Negative|H||A^S|F|||202003181346
OBR|4|40654^LAB|00030643^1803:H00003R^LAB^180320:H3^40654|210.7200^APCAT^APCA Titer^APCA^5271-2^5271-2||202003181346|202003181342|||||||202003181342||||||||||LAB|I||||

MSH|^~\&|LAB|RCH|||202003181346||ORU^R01|4187696|D|2.3|||AL|NE
PID|1||RC00008163|RC7824|FHLOOSEN^PLIS^||19240204|M||||||||||RC001189/19|9698717831
OBR|1|40654^LAB|00030643^1803:H00003R^LAB^180320:H3^40654|210.2700^ANA^Anti-Nuclear Antibody Group^^^5047-6||202003181346|202003181342|||||||202003181342||||||||||LAB|F||||
OBX|1|ST|210.2850^ANAS R^ANA Screen^^5047-6^5047-6|1|0.5^^Y||<0.7|N||A^S|F|||202003181346
NTE|1||Antinuclear antibodies, including antibodies to dsDNA or to
NTE|2||extractable nuclear antigens (SS-A, SS-B, Sm, U1RNP, Scl-70,
NTE|3||Jo-1, and Centromere), are not present.
NTE|4||
NTE|5||Further testing is not indicated; however, if required,
NTE|6||please contact a Hematopathologist.
OBR|2|40654^LAB|00030643^1803:H00003R^LAB^180320:H3^40654|210.3200^DNA^Anti-dsDNA Antibody Group^^^32677-7||202003181346|202003181342|||||||202003181342||||||||||LAB|F||||
OBX|1|ST|210.3290^DNAS R^Anti-DNA (Double Stranded)^^32677-7^32677-7|1|9.0^^Y|IU/mL|<10.0|N||A^S|F|||202003181346
OBR|3|40654^LAB|00030643^1803:H00003R^LAB^180320:H3^40654|210.7000^APCA^Anti-Parietal Cell Antibody^^^26969-6||202003181346|202003181342|||||||202003181342||||||||||LAB|F||||
OBX|1|ST|210.7100^APCAS^Anti-Parietal Cell Antibody^APCA^26969-6^26969-6|1|Positive^^N||Negative|H||A^S|F|||202003181346
OBR|4|40654^LAB|00030643^1803:H00003R^LAB^180320:H3^40654|210.7200^APCAT^APCA Titer^APCA^5271-2^5271-2||202003181346|202003181342|||||||202003181342||||||||||LAB|F||||
OBX|1|ST|210.7200^APCAT^APCA Titer^APCA^5271-2^5271-2|1|5^^Y||<40|N||A^S|F|||202003181346
NTE|1||AMA, ASMA and/or APCA is weakly positive to a titer of 40.
NTE|2||Clinical correlation is required.

MSH|^~\&|LAB|RCH|||202003181347||ORU^R01|4187698|D|2.3|||AL|NE
PID|1||RC00008163|RC7824|FHLOOSEN^PLIS^||19240204|M||||||||||RC001189/19|9698717831
OBR|1|40656^LAB|00030644^1803:H00004R^LAB^180320:H4^40656|210.4700^AMA^Anti-Mitochondrial Antibody^^^17284-1||202003181347|202003181347|||||||202003181347||||||||||LAB|F||||
OBX|1|ST|210.4750^AMAS^Anti-Mitochondrial Antibody^AMA^17284-1^17284-1|1|Positive^^N||Negative|H||A^S|F|||202003181347
OBR|2|40656^LAB|00030644^1803:H00004R^LAB^180320:H4^40656|210.4800^AMAT^AMA Titer^AMA^5247-2^5247-2||202003181347|202003181347|||||||202003181347||||||||||LAB|F||||
OBX|1|ST|210.4800^AMAT^AMA Titer^AMA^5247-2^5247-2|1|50^^Y||<40|H||A^S|F|||202003181347
NTE|1||Antimitochondrial antibodies raises consideration of primary
NTE|2||biliary cirrhosis and may antedate other evidence of the
NTE|3||disease.  They may also be detected in patients with diffuse
NTE|4||systemic sclerosis (scleroderma), Sjogren's syndrome and
NTE|5||SLE.

MSH|^~\&|LAB|RCH|||202003181347||ORU^R01|4187699|D|2.3|||AL|NE
PID|1||RC00008163|RC7824|FHLOOSEN^PLIS^||19240204|M||||||||||RC001189/19|9698717831
OBR|1|40656^LAB|00030644^1803:H00004R^LAB^180320:H4^40656|210.4700^AMA^Anti-Mitochondrial Antibody^^^17284-1||202003181347|202003181347|||||||202003181347||||||||||LAB|F||||
OBX|1|ST|210.4750^AMAS^Anti-Mitochondrial Antibody^AMA^17284-1^17284-1|1|Positive^^N||Negative|H||A^S|F|||202003181347
OBR|2|40656^LAB|00030644^1803:H00004R^LAB^180320:H4^40656|210.4800^AMAT^AMA Titer^AMA^5247-2^5247-2||202003181347|202003181347|||||||202003181347||||||||||LAB|F||||
OBX|1|ST|210.4800^AMAT^AMA Titer^AMA^5247-2^5247-2|1|50^^Y||<40|H||A^S|F|||202003181347
NTE|1||Antimitochondrial antibodies raises consideration of primary
NTE|2||biliary cirrhosis and may antedate other evidence of the
NTE|3||disease.  They may also be detected in patients with diffuse
NTE|4||systemic sclerosis (scleroderma), Sjogren's syndrome and
NTE|5||SLE.